Go to the list of all blogs
Alicia's Avatar
published in Blogs
May 06, 2026
TickeronGET DAILY SIGNALS
Why Is Alphatec Holdings (ATEC) Stock Down -30% Today?

Why Is Alphatec Holdings (ATEC) Stock Down -30% Today?

Key Takeaways

  • ATEC shares plunged 30.55% to close at $7.11 from the previous close of $10.23.
  • Primary catalyst: Q1 2026 earnings miss with revenue of $192 million versus expectations of $197.5 million, driven by weakness in EOS imaging sales.
  • EPS of -$0.22 missed consensus of -$0.01; company lowered full-year EOS revenue guidance to $77 million while maintaining surgical revenue outlook at $805 million.
  • Trading volume spiked to over 14 million shares, well above the average of 2.66 million, indicating heavy selling pressure.
  • Move diverged sharply from broader market, with Nasdaq up over 1% and medical devices ETF (IHI) down only 0.28%.
  • Traders watching EOS business recovery, Q2 execution, and surgeon adoption metrics ahead of next earnings in late July.

Breaking Down the Sharp Decline in ATEC

I've been keeping an eye on ATEC, the medical technology company focused on spinal implants, instruments, biologics, and imaging systems for spine surgery. Yesterday, its shares fell 30.55%, closing at $7.11 after the prior session's $10.23. The market's reaction came right after the Q1 2026 earnings release on May 5, triggered by a revenue miss and reduced guidance for the EOS imaging segment—even as the core surgical business showed solid growth.

The Earnings Details and Guidance Shift

Alphatec posted Q1 revenue of $192.1 million, a 14% increase year-over-year, but it fell short of the $197.5 million consensus. The surgical revenue segment, which forms the backbone of the business, grew 17% to $178 million, fueled by 21% higher case volumes and 23% more surgeons, particularly in lateral, ALIF, and cervical procedures. That said, EOS imaging revenue dropped 18% to $14 million, mainly from fewer system deliveries, which pulled the overall numbers down.

On the bottom line, GAAP EPS was -$0.22, missing the expected -$0.01 loss. The net loss improved to $33.9 million from $51.9 million last year, thanks to reduced litigation costs. Adjusted EBITDA rose to $21 million. Management noted that EOS fell short of internal goals and plans to ramp up sales and marketing efforts there.

For the full year, guidance now calls for $882 million in total revenue (15% growth), with surgical revenue unchanged at $805 million (17% growth) and EOS trimmed to $77 million. The adjusted EBITDA target remains $134 million, signaling confidence in margin expansion.

Trading Volume and Broader Market Comparison

Trading volume surged to 14 million shares—more than five times the average of 2.66 million—reflecting the strong investor response. The drop gapped shares below recent support at $9-10, approaching 52-week lows of $6.85-9.11. What stands out is how ATEC diverged from peers: the IHI medical devices ETF dipped only 0.28%, while the XLV healthcare ETF rose 0.39%. The Nasdaq Composite gained 1.03%, and the S&P 500 advanced 0.81%, pointing to company-specific concerns.

What I'm Watching for ATEC's Recovery

From what I see, the key will be EOS sales rebounding through enhanced sales initiatives and sustained procedure growth in Q2. The next earnings report is due in late July, where execution against the $882 million revenue and $134 million adjusted EBITDA goals will be critical. Analysts hold a bullish consensus with average price targets around $23-24, though adjustments like Canaccord's cut to $23 highlight EOS worries. Spine surgery innovation offers sector tailwinds, but risks from high debt and competition—such as from GMED—remain. Macro factors and healthcare demand will also play a role.

I also checked this using Tickeron’s AI Screener to compare ATEC against industry peers, which helped contextualize the surgical segment's strength.

Why I Rely on Tickeron's Trending AI Robots

In my own trading and research, I often turn to Tickeron’s Trending AI Robots page to spot top-performing AI-driven bots amid shifting markets. Tickeron runs hundreds of these bots across thousands of tickers, using strategies like trend-following, mean reversion, and momentum on various timeframes. The trending list focuses on those with the best risk-adjusted returns, win rates, and consistency—backed by metrics like Sharpe ratio, maximum drawdown, and profit factor. I've found it useful to test them in virtual portfolios before going live; it's a practical way to sharpen my edge without starting from scratch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Related Ticker: ATEC

Contributor

Alicia's AvatarAlicia|Beginner

ATEC in downward trend: 10-day moving average broke below 50-day moving average on November 03, 2026

The 10-day moving average for ATEC crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATEC as a result. In 65 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for ATEC turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 31 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

ATEC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATEC's RSI Oscillator exited the oversold zone, 28 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATEC advanced for three days, in 268 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

ATEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 217 of 253 cases where ATEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. ATEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (-95.212) is very low in comparison to the industry average of (4.142). P/E Ratio (-10.479) is within average values for comparable stocks, (3.291). ATEC's Projected Growth (PEG Ratio) (91.200) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.980) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company with interests in medical equipment and supplies

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1950 Camino Vida Roble
Phone
+1 760 431-9286
Employees
913
Web
https://www.atecspine.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.